Hampton Likely To Have Difficult Start As GSK Chairman
This article was originally published in The Tan Sheet
Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring in the previously announced asset swap with Novartis, and increasing generic competition to its leading products.
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.